It is hereby submitted that revised outcome of Board Meeting is being filed here with reference to the previously filed outcome of Board Meeting vide Acknowledgement Number 10616056 for ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kimia Biosciences filed a revised outcome of its August 14, 2025 board meeting, correcting the meeting closure time from 2:30 PM to 1:30 PM as directed by BSE. The board approved Q1 FY26 (quarter ended June 30, 2025) standalone unaudited results, with revenue from operations rising modestly to Rs. 2,358.41 lakhs from Rs. 2,239.93 lakhs YoY, but profit after tax falling sharply to Rs. 60.40 lakhs from Rs. 143.70 lakhs, and EPS dropping to Rs. 0.13 from Rs. 0.30. The board also noted a BSE warning letter dated July 25, 2025 over non-disclosure of an AGM extension, approved raising an unsecured loan of Rs. 2 crore at 8% per annum, and appointed Mr. Pradip Kumar Sharma as the new Chief Financial Officer with immediate effect.
For shareholders, the headline concern is the steep YoY drop in profitability (PAT down ~58%) even as revenue grew only ~5%, indicating margin pressure that may weigh on the stock. The BSE warning letter for a disclosure lapse is a minor governance red flag, while the Rs. 2 crore loan and new CFO appointment signal fresh capital and leadership at a small-cap pharma company.